MacroGenics, Inc. (MGNX)
Last updated: 2026-10-22 04:28:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Summary
MacroGenics, Inc. (MGNX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $3.60, with a market capitalization of $212.12M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.29 to $5.08. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$212.12M | |
$3.58 | |
$41.00 | |
$0.99 | |
$3.49 | |
204.19K | |
579.32K | |
-- | |
$5.08 | |
$1.29 | |
-- | |
-- |
MacroGenics, Inc. (MGNX) Latest Closing Stock Price
MacroGenics, Inc. (MGNX) last closed at $3.49 as of 2026-10-21 23:31:00, unchanged from the previous close of $3.49.
During the latest regular trading session, MGNX traded between $0.99 and $41.00, with a volume of 204.19K shares. The closing price was near the lower end and near the middle of its 52-week range.
MacroGenics, Inc. (MGNX) 7-Day Stock Price Change
Over the past seven days, MacroGenics, Inc. (MGNX) moved from $3.72 to $3.60, representing a decline of 3.25% ($0.12).
The stock traded between $3.19 and $3.76 during the period. The latest price is near the upper end of the 7-day range, indicating moderate downward.
The average daily volume was 518.90 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
MGNX 52-Week Price Position
Position in Range: 60.9%
MGNX is currently trading at $3.60, placing it 60.9% of the way from its 52-week low of $1.29 to its 52-week high of $5.08. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is MacroGenics, Inc. (MGNX)?
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
MacroGenics, Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 293 |
| Exchange | NASDAQ |
| Company Website |
How to Buy MacroGenics, Inc. (MGNX) Stock on MEXC
Eligible investors can buy real shares of MacroGenics, Inc. (MGNX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is MacroGenics, Inc. (MGNX) stock price today?
2.Is MGNX stock going up or down today?
3.What is MGNX pre-market price?
4.What is MGNX after-hours price?
5.Is MGNX stock trading now?
6.Where does MGNX sit relative to its 52-week high and low?
7.What sector is MacroGenics, Inc. in?
8.What is MacroGenics, Inc.'s market capitalization and where is it listed?
9.How is MGNX valued in terms of P/E ratio and EPS?
10.Does MacroGenics, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
MGNX Stock Calculator
Estimate the value between MGNX shares and USD.
MGNX Shares to USD
1.00 MGNX shares = 3.599 USD
Calculations are estimates based on the latest available price and are for reference only.


